Last reviewed · How we verify
Menjugate®
Menjugate is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against serogroup C meningococcal polysaccharide capsule.
Menjugate is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against serogroup C meningococcal polysaccharide capsule. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C.
At a glance
| Generic name | Menjugate® |
|---|---|
| Also known as | MenC-CRM197vaccine, MenC-CRM, Novartis' meningococcal serogroup C CRM197 protein conjugated vaccine. |
| Sponsor | GlaxoSmithKline |
| Drug class | Meningococcal conjugate vaccine |
| Target | Meningococcal serogroup C polysaccharide capsule |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine consists of meningococcal serogroup C polysaccharide conjugated to a protein carrier (tetanus toxoid), which enhances immunogenicity and T-cell dependent immune response. This conjugation allows the vaccine to elicit both IgG antibodies and immunological memory, providing protection against invasive meningococcal disease caused by Neisseria meningitidis serogroup C.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C in infants, children, adolescents, and adults
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability
- Drowsiness
- Loss of appetite
Key clinical trials
- A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study (PHASE1)
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers (PHASE3)
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose (PHASE2)
- Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age (PHASE2)
- Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children (PHASE3)
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants (PHASE2)
- Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Menjugate® CI brief — competitive landscape report
- Menjugate® updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI